Pharmacology and clinical efficacy of dalfampridine for treating multiple sclerosis

Bibliography

• Chwieduk CM, Keating GM. Dalfampridine extended release: in multiple sclerosis. CNS Drugs 2010;24(10):883-91
   PubMed Web of Science ®Google Scholar
• Goodman AD, Stone RT. Enhancing neural transmission in multiple sclerosis (4-aminopyridine therapy). Neurotherapeutics 2013;10(1):106-10
   PubMed Web of Science ®Google Scholar
• Blight AR. Treatment of walking impairment in multiple sclerosis with dalfampridine. Ther Adv Neurol Disord 2011;4(2):99-109
   PubMedGoogle Scholar
• Jensen HB, Ravnborg M, Dalgas U, et al. 4-Aminopyridine for symptomatic treatment of multiple sclerosis: a systematic review. Ther Adv Neurol Disord 2014;7(2):97-113
   PubMed Web of Science ®Google Scholar
• Preiningerova JL, Baumhackl U, Csepany T, et al. Recommendations for the use of prolonged-release fampridine in patients with multiple sclerosis (MS). CNS Neurosci Ther 2013;19(5):302-6
   PubMed Web of Science ®Google Scholar
• Hersh C, Rae-Grant A. Extended-release dalfampridine in the management of multiple-sclerosis-related walking impairment. Ther Adv Neurol Disord 2012;5(4):199-204
   PubMedGoogle Scholar
• Dunn J, Blight A. Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis. Curr Med Res Opin 2011;27(7):1415-23
   PubMed Web of Science ®Google Scholar
• Mathiesen HK, Sorensen PS. Prolonged-release fampridine improves walking in a proportion of patients with multiple sclerosis. Expert Rev Neurother 2013;13(12):1309-17
   PubMed Web of Science ®Google Scholar
• Miravalle AA. Guidelines and best practices for appropriate use of dalfampridine in managed care populations. Am J Manag Care 2011;17(Suppl 5 Improving):S154-60
   PubMedGoogle Scholar
• Vollmer T, Henney HRIII. Pharmacokinetics and tolerability of single escalating doses of fampridine sustained release tablets in patients with multiple sclerosis: a phase I-II, open-label trial. Clin Ther 2009;31(10):2206-14
   PubMed Web of Science ®Google Scholar
• Smith W, Swan S, Marbury T, et al. Single-dose pharmacokinetics of sustained-release fampridine (fampridine-SR) in healthy volunteers and adults with renal impairment. J Clin Pharmacol 2010;50(2):151-9
   PubMed Web of Science ®Google Scholar
• Samara E, Winkle P, Pardo P, et al. Pharmacokinetics of dalfampridine extended release 7.5-mg tablets in healthy subjects and individuals with mild and moderate renal impairment: an open-label study. J Clin Pharmacol 2014;54(1):53-60
   PubMed Web of Science ®Google Scholar
• Henney HR, Blight AR. Walking impairment in patients with multiple sclerosis – a new therapeutic approach and clinical potential of dalfampridine extended release tablets. Degener Neurol Neuromuscul Dis 2012;2:53-64
   PubMedGoogle Scholar
• Judge SI. Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment. Pharmacol Ther 2006;111:224-59
   PubMed Web of Science ®Google Scholar
• Espejo C, Montalban X. Dalfampridine in multiple sclerosis: from symptomatic treatment to immunomodulation. Clin Immunol 2012;142(1):84-92
   PubMed Web of Science ®Google Scholar
• Karimi-Abdolrezaee S, Eftekharpour E, Fehlings MG. Temporal and spatial patterns of Kv1.1 and Kv1.2 protein and gene expression in spinal cord white matter after acute and chronic spinal cord injury in rats: implications for axonal pathophysiology after neurotrauma. Eur J Neurosci 2004;19(3):577-89
   PubMed Web of Science ®Google Scholar
• Vautier F, Belachew S, Chittajallu R, et al. Shaker-type potassium channel subunits differentially control oligodendrocyte progenitor proliferation. Glia 2004;48:337-45
   PubMed Web of Science ®Google Scholar
• Goodman AD, Cohen JA, Cross A, et al. Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study. Mult Scler 2007;13:357-68
   PubMed Web of Science ®Google Scholar
• Goodman AD, Brown TR, Cohen JA, et al. Dose comparison trial of sustained-release fampridine in multiple sclerosis. Neurology 2008;71:1134-41
   PubMed Web of Science ®Google Scholar
• Goodman AD, Brown TR, Krupp L, et al. Sustained release of oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 2009;373(9665):732-8
   PubMed Web of Science ®Google Scholar
• Goodman AD, Brown TR, Edwards KR, et al. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol 2010;68(4):494-502
   PubMed Web of Science ®Google Scholar
• Schapiro R, Goodman AD, Brown T, et al. Dalfampridine improves walking in MS patients: pooled data from 3 clinical trials [abstract]. 21st Annual Meeting of the Consortium of Multiple Sclerosis Centres; 30 May – 02 June 2010; Washington, DC
   Google Scholar
• Goodman AD, Brown T, Edwards K, et al. Characteristics of walking speed improvement observed in three placebo-controlled studies of dalfampridine extended release tablets 10 mg bid in patients with multiple sclerosis [abstract]. 62nd Annual Meeting of the American Academy of Neurology; 10 – 17 April 2010; Toronto
   Google Scholar
• Limone BL, Sidovar MF, Coleman CI. Estimation of the effect of dalfampridine on health utility by mapping the MSWS-12 to the EQ-5D in multiple sclerosis patients. Health Qual Life Outcomes 2013;11(1):105
   PubMed Web of Science ®Google Scholar
• Goodman A; on behalf of the MS-F203, MS-F204, and extension study investigators. Updated analysis of open-label extension studies of dalfampridine extended release tablets in multiple sclerosis [abstract]. Mult Scler 2011;17(Suppl):S245-6
   PubMedGoogle Scholar
• Goodman AD, Brown T, Edwards K, et al. Interim analysis of open-label extension studies of dalfampridine extended release tablets in patients with multiple sclerosis [abstract]. 62nd Annual Meeting of the American Academy of Neurology; 10 – 17 April 2010; Toronto
   Google Scholar
• Jensen H, Ravnborg M, Mamoei S, et al. Changes in cognition, arm function and lower body function after Slow-Release Fampridine treatment. Mult Scler 2014: pii: 1352458514533844. [ Epub ahead of print]
   Web of Science ®Google Scholar
• Macdonell R, Sorensen PS, Pozzilli C, et al. Long-term prolonged-release fampridine treatment and health-related quality of life outcome: 12-months analysis of the ENABLE study. 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis; Copenhagen; 2005. p. Poster P665
   Google Scholar
• Lee A, Wang P, Yeh M. Evaluation of patient health status in the PR-fampridine ENABLE study using SF-36–derived utility scores. 2014 Joint ACTRIMS-ECTRIMS Meeting; 10 – 13 September 2014; Boston, MA, USA. p. Poster 785
   Google Scholar
• Rabadi MH, Kreymborg K, Vincent AS. Sustained-release fampridine (4-aminopyridine) in multiple sclerosis: efficacy and impact on motor function. Drugs R D 2013;13(3):175-81
   PubMedGoogle Scholar
• Prugger M, Berger T. Assessing the long-term clinical benefit of prolonged-release fampridine tablets in a real-world setting: a review of 67 cases. Patient Relat Outcome Meas 2013;4:75-85
   PubMedGoogle Scholar
• Ruck T, Bittner S, Simon OJ, et al. Long-term effects of dalfampridine in patients with multiple sclerosis. J Neurol Sci 2014;337(1-2):18-24
   PubMed Web of Science ®Google Scholar
• Zeller D, Reiners K, Bräuninger S, et al. Central motor conduction time may predict response to fampridine in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2014;85(6):707-9
   PubMed Web of Science ®Google Scholar
• Zorner B, Reuter K, Filli L, et al. Detailed characterization of the effects of prolonged release fampridine on walking function in patients with multiple sclerosis (FAMPKIN-IIT). 2014 Joint ACTRIMS-ECTRIMS Meeting; 10 – 13 September 2014; Boston, MA, USA. p. Poster 911
   Google Scholar
• Weller D, Zorner B, Sutter T, et al. Prolonged-release fampridine enhances physical activity during everyday life in patients with multiple sclerosis (FAMPKIN STUDY). 2014 Joint ACTRIMS-ECTRIMS Meeting; 10 – 13 September 2014; Boston, MA, USA. p. Poster 906
   Google Scholar
• Lorincz L, Zorner B Weller D, et al. Kinematic analysis of fampridine induced modifications of the gait pattern in individuals with multiple sclerosis (FAMPKIN STUDY). 2014 Joint ACTRIMS-ECTRIMS Meeting; 10 – 13 September 2014; Boston, MA, USA. p. Poster 908
   Google Scholar
• Broicher SD, Geisseler O, German N, et al. Effects of long term treatment with prolonged-release fampridine on cognitive functioning in patients with multiple sclerosis: an investigator initiated open label, mono center follow-up study of FAMPKIN. 2014 Joint ACTRIMS-ECTRIMS Meeting; 10 – 13 September 2014; Boston, MA, USA. p. Poster 941
   Google Scholar
• Filli L, Kapitza S, Reuter K, et al. Long-term effects of fampridine on walking ability in patients with multiple sclerosis: a phase II, open-label, uncontrolled, monocenter study (FAMPKIN EXT.STUDY). 2014 Joint ACTRIMS-ECTRIMS Meeting; 10 – 13 September 2014; Boston, MA, USA. p. Poster 929
   Google Scholar
• Flisher L, Koch M, Christofi G, et al. PR-Fampridine improves walking and quality of life in people with MS related severe walking impairment: a pragmatic observational study. 2014 Joint ACTRIMS-ECTRIMS Meeting; 10 – 13 September 2014; Boston, MA, USA. p. Poster 935
   Google Scholar
• Guyot MA, Donze C, Hichem K, et al. Dalfampridine improves spasticity and fatigue in multiple sclerosis. 2014 Joint ACTRIMS-ECTRIMS Meeting; 10 – 13 September 2014; Boston, MA, USA. p. Poster 788
   Google Scholar
• Hupperts R, Lycke J, Short C, et al. Walking ability and balance in patients with multiple sclerosis treated with prolonged-release fampridine: randomized, double-blind MOBILE Study. 2014 Joint ACTRIMS-ECTRIMS Meeting; 10 – 13 September 2014; Boston, MA, USA. p. Poster 922
   Google Scholar
• Ongagna JC, Berthe C, Courtois S, et al. Prolonged-release Fampyra post-marketing experience in Alsace, France. 2014 Joint ACTRIMS-ECTRIMS Meeting; 10 – 13 September 2014; Boston, MA, USA. p. Poster 932
   Google Scholar
• Savin Z, Leibkowicz I, Glass-Marmor L, et al. Effect of Fampridine (4-aminopyridine) on the manual function of patients with multiple sclerosis. 2014 Joint ACTRIMS-ECTRIMS Meeting; 10 – 13 September 2014; Boston, MA, USA. p. Poster 918
   Google Scholar
• Palli S, Sidovar M, Grabner M, et al. Treatment patterns and budget impact of dalfampridine in multiple sclerosis: a retrospective claims database analysis. 2014 Joint ACTRIMS-ECTRIMS Meeting; 10 – 13 September 2014; Boston, MA, USA. p. Poster 010
   Google Scholar
• Haut SR, Bienen EJ, Miller A. Clinical overview of the seizure risk of dalfampridine. Expert Opin Drug Saf 2012;11(4):651-7
   PubMed Web of Science ®Google Scholar
• Burton JM, Bell CM, Walker SE, et al. 4-aminopyridine toxicity with unintentional overdose in four patients with multiple sclerosis. Neurology 2008;71(22):1833-4
   PubMed Web of Science ®Google Scholar
• Schwam E. Severe accidental overdose of 4-aminopyridine due to a compounding pharmacy error. J Emerg Med 2011;41(1):51-4
   PubMed Web of Science ®Google Scholar
• Ballesta Méndez M, van Pesch V, Capron A, Hantson P. Prolonged toxic encephalopathy following accidental 4-aminopyridine overdose. Case Rep Neurol Med 2014;2014:237064
   Google Scholar
• Laroni A, Brogi D, Morra VB, EAP Investigators. Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial. BMC Neurol 2014;14:65
   PubMed Web of Science ®Google Scholar
• Jara M, Barker G, Henney HRIII. Dalfampridine extended release tablets: 1 year of postmarketing safety experience in the US. Neuropsychiatr Dis Treat 2013;9:365-70
   PubMed Web of Science ®Google Scholar
• Capra C, Battaglia MA, Gaudioso A, et al. The MoSt Project – more steps in multiple sclerosis: a Delphi method consensus initiative for the evaluation of mobility management of MS patients in Italy. J Neurol 2014;261(3):526-32
   PubMed Web of Science ®Google Scholar